Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

d a Phase 3 study of intravenous (i.v.) peramivir for seasonal influenza in the outpatient setting. Patient enrollment is underway in Japan and other countries in eastern Asia. The study will enroll approximately 1,000 patients. Shionogi initiated this Phase 3 study based on positive clinical results from a Phase 2 study that investigated the efficacy and safety of a single administration of i.v. peramivir 300 mg or 600 mg for the treatment of seasonal influenza in the outpatient setting. The Phase 2 study results were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th Annual Meeting in a poster titled "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients." In the Phase 2 study, the primary efficacy endpoint, time to alleviation of symptoms (TTAS), was significantly shorter in both peramivir arms compared to placebo.

  • BioCryst will present results from the previously announced exploratory Phase 2 study of i.v. peramivir in patients hospitalized for acute serious or potentially life-threatening influenza in an oral presentation at the XI International Symposium on Respiratory Viral Infections, being held in Bangkok, Thailand, February 19-22, 2009.

Forodesine HCl Program

  • BioCryst continues to enroll patients in the Phase 2 pivotal study of Forodesine HCl in patients with cutaneous T-cell lymphoma (CTCL), and has enrolled more than half of the targeted patients. The study will enroll approximately 130 patients and the Company expects to report top-line data in the first half of 2010.

  • BioCryst announced interim data from the ongoing Forodesine HCl Phase 2 program in patients with chronic lymphocytic leukemia (CLL) and data from a healthy subject
    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... detection and quantification of partially hydrolyzed gluten in foods, has been accepted by ... the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
(Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management ... over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... 21, 2011 The report " ... Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 ... major market drivers, restraints, and opportunities in North America, ... tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic ...
... 18, 2011 Percentage of revenues from ... medical relief organization building a hospital in Ethiopia ... technical and medical information products and services, announced today ... (ICA) through its "Pillars of Hope" ...
... W.Va. Recent studies conducted at Marshall University have demonstrated ... used to increase the fuel efficiency of automobile engines -- ... this process is associated with liver damage. The ... his colleagues at Marshall,s Center for Diagnostic Nanosystems indicate there ...
Cached Biology Technology:MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 2Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 3Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver 2
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... College London has discovered 24 new genes that cause refractive ... major cause of blindness and visual impairment worldwide, and currently ... journal Nature Genetics , reveal genetic causes of the ... of preventing the condition in the future. ...
... roles in the same biological pathways change their rate of ... discover their functions, said a researcher at the University of ... GENETICS . Humans have nearly 21,000 genes that make ... genes have not been fully determined, said lead investigator Nathan ...
... and Germany have identified that the proteins lamin A ... holding silent genes in their correct position at the ... . A deviation from their normal position will cause ... disease and muscle wasting. 2. For hundreds of ...
Cached Biology News:New genes for short-sightedness identified 2Evaluating evolutionary rates could shed light into functions of uncharacterized genes 2A*STAR scientists' groundbreaking discovery of nucleus structure crucial to understanding diseases 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: